loading page

Two cases of AMeD syndrome with isochromosome 1q treated with allogeneic stem cell transplantation
  • +7
  • Mari Kagajo,
  • Kyoko Moritani,
  • Mayumi Iwamoto,
  • Machiko Miyamoto,
  • Tsuyoshi Imai,
  • Hamada Motoharu,
  • Manabu Wakamatsu,
  • Hideki Muramatsu,
  • Minenori Eguchi-Ishimae,
  • Mariko Eguchi
Mari Kagajo
Ehime Daigaku Daigakuin Igakukei Kenkyuka Igakubu

Corresponding Author:[email protected]

Author Profile
Kyoko Moritani
Ehime Daigaku Daigakuin Igakukei Kenkyuka Igakubu
Author Profile
Mayumi Iwamoto
Ehime Daigaku Daigakuin Igakukei Kenkyuka Igakubu
Author Profile
Machiko Miyamoto
Ehime Daigaku Daigakuin Igakukei Kenkyuka Igakubu
Author Profile
Tsuyoshi Imai
Kokuritsu Byoin Kiko Shikoku Kodomoto Otonano Iryo Center
Author Profile
Hamada Motoharu
Nagoya Shiritsu Daigaku Daigakuin Igaku Kenkyuka Igakubu
Author Profile
Manabu Wakamatsu
Nagoya University Graduate School of Medicine
Author Profile
Hideki Muramatsu
Nagoya University Graduate School of Medicine
Author Profile
Minenori Eguchi-Ishimae
Ehime Daigaku Daigakuin Igakukei Kenkyuka Igakubu
Author Profile
Mariko Eguchi
Ehime Daigaku Daigakuin Igakukei Kenkyuka Igakubu
Author Profile

Abstract

AMeD syndrome is characterized by aplastic anemia, mental retardation, short stature, and microcephaly and is caused by digenic mutations in the aldehyde dehydrogenase 2 ( ALDH2) and alcohol dehydrogenase 5 ( ADH5) genes. We have successfully performed hematopoietic stem cell transplantation in two patients with AMeD syndrome and isochromosome 1q. AMeD syndrome with myelodysplastic syndrome or acute myeloblastic leukemia generally has a poor prognosis; however, early diagnosis may improve treatment response. Although the gain of 1q has been considered as a form of early clonal evolution in Fanconi anemia, it may be an equally important finding observed in AMeD syndrome.